Drug Profile

Research programme: TREX-1 inhibitors - Tempest Therapeutics

Latest Information Update: 14 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tempest Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action Three prime repair exonuclease 1 expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

14 Apr 2023 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 114^th Annual Meeting of the American Association for Cancer Research (AACR-2023)
10 Apr 2023 Tempest plans to activate IND-enabling activities in 2023
15 Apr 2022 Tempest Therapeutics has pending patent applications for TRX 1 in the USA and Taiwan and a pending PCT application

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com